Hayırlı uğurlu olsun Allah şifa versin Ali Kamal
Covid-19 Koronavirüs Haberleri | Eris Varyantı Türkiye'de
- Konbuyu başlatan Emrah Yıldırım
- Başlangıç tarihi
Hayırlı uğurlu olsun Allah şifa versin Ali Kamal
bu aralar zaman yok hiç. yoksa anında yazılcam salona. tek sosyal aktivitem foruma 1 2 saat yazmak onun dışında full dükkandayım+ evdeyken de excel dosyalarının içindeyim. daha da yoğunlaşıyor işler muhtemelen 1 2gün içinde forumdan tüyücem uzun bir süreliğine
fıtık tetikliyor muhtemelen diyet+spor başlıcam en kısa zamanda.
Eyvallah dostlar. Esim halen pek iyi degil Kizimiz düne göre daha iyi gibi. Ben yorgunum basim agriyor ama atesim yok öyle takiliyoruz
Çok geçmiş olsun 🙏 Umarım en kısa sürede hepiniz sağlığınıza kavuşursunuz.
Allah hepinizden razi olsun
OMT adviseert harde lockdown, kabinet pleegt zaterdag spoedoverleg | Coronavirus | NU.nl
Het Outbreak Management Team (OMT) adviseert het demissionaire kabinet om een harde lockdown in te voeren vanwege de omikronvariant van het coronavirus, zeggen bronnen tegen het AD en RTL Nieuws. Het kabinet pleegt zaterdagmiddag digitaal spoedoverleg om het OMT-advies te bespreken, waarna er...www.nu.nl
RIP vrijheid @Ibrahim Özveren @Hakan Duz
Şemsiye açılıyor. Halbuki vaka sayıları bir nebze düştü. Belliki noel ve yılbaşında oluşacak olasi sorunlari onceden engellemek için kilit vuracaklar ulkeye
Uzuldum ustat.. Buyuk gecmis olsun.. Ayni durum bizdede vuku buldu. Hanim hamileyken aşı olsak mi olmasak mi cok tartistik ve sonunda olmaya karar verdik. Dogumdan sonra ise plasenta artiklari oluştu ve bunlar hastalık yapmaya başladı. Covid ten mi yoksa aşıdan mi olduğu suan arastiriliyor. Nalet bir dönem gerçekten.. Rabbim şifa buyursun
geçmiş olsun renkdaş. tez şifa bulursunuz inşallah.
almanya 53k vaka 479 ölüm açıklamış dün😳
Aşılarla alakalı çok fazla dezenformasyon var. 3. dozu bugün oldum ama o kadar garip şeyler okuyyorum ki gecenin bu saatinde, keşke olmasa mıydım diyorum..
Uludağ da yılbaşı için ekstraya giden arkadaş var.Gidecegi işletme şuan belli değil yılbaşında kapanma kararı alabilir hükümet demiş.Haber bekliyordu arkadaş
Sizede büyük gecmis olsun Reis
Allah şifa versin @Kolpa Kemal Kürek
Her sene aynı şeyi yapamazlar bana göre, virus kalıcı ve hep mutasyona uğrayacak. Artıkı devletler bunu kabul etmeleri lazım ve ona göre kurallar koymaları lazım.
HAP çıkarmışlar.
U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.
The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals.
The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorized drugs against the disease require an IV or an injection.
An antiviral pill from Merck also is expected to soon win authorization. But Pfizer's drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severe disease.
“The efficacy is high, the side effects are low and it’s oral. It checks all the boxes,” said Dr. Gregory Poland of the Mayo Clinic. “You’re looking at a 90% decreased risk of hospitalization and death in a high-risk group — that’s stunning.”
The Food and Drug Administration authorized Pfizer's drug for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalization. That includes older people and those with conditions like obesity and heart disease. Children eligible for the drug must weigh at least 88 pounds (40 kilograms).
The pills from both Pfizer and Merck are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.
Pfizer currently has 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. Federal health officials are expected to ration early shipments to the hardest hit parts of the country. Pfizer said the small supply is due to the manufacturing time — currently about nine months. The company says it can halve production time next year.
The U.S. government has agreed to purchase enough Paxlovid to treat 10 million people. Pfizer says it's on track to produce 80 million courses globally next year, under contracts with the U.K., Australia and other nations.
Health experts agree that vaccination remains the best way to protect against COVID-19. But with roughly 40 million American adults still unvaccinated, effective drugs will be critical to blunting the current and future waves of infection.
The U.S. is now reporting more than 140,000 new infections daily and federal officials warn that the omicron variant could send case counts soaring. Omicron has already whipped across the country to become the dominant strain, federal officials confirmed earlier this week.
Against that backdrop, experts warn that Paxlovid's initial impact could be limited.
For more than a year, biotech-engineered antibody drugs have been the go-to treatments for COVID-19. But they are expensive, hard to produce and require an injection or infusion, typically given at a hospital or clinic. Also, laboratory testing suggests the two leading antibody drugs used in the U.S. aren't effective against omicron.
Pfizer’s pill comes with its own challenges.
Patients will need a positive COVID-19 test to get a prescription. And Paxlovid has only proven effective if given within five days of symptoms appearing. With testing supplies stretched, experts worry it may be unrealistic for patients to self-diagnose, get tested, see a physician and pick up a prescription within that narrow window.
“If you go outside that window of time I fully expect the effectiveness of this drug is going to fall,” said Andrew Pekosz, a Johns Hopkins University virologist.
The FDA based its decision on company results from a 2,250-patient trial that showed the pill cut hospitalizations and deaths by 89% when given to people with mild-to-moderate COVID-19 within three days of symptoms. Less than 1% of patients taking the drug were hospitalized and none died at the end of the 30-day study period, compared with 6.5% of patients hospitalized in the group getting a dummy pill, which included nine deaths.
Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.
The U.S. will pay about $500 for each course of Pfizer's treatment, which consists of three pills taken twice a day for five days. Two of the pills are Paxlovid and the third is a different antiviral that helps boost levels of the main drug in the body.
U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.
The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals.
The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorized drugs against the disease require an IV or an injection.
An antiviral pill from Merck also is expected to soon win authorization. But Pfizer's drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severe disease.
“The efficacy is high, the side effects are low and it’s oral. It checks all the boxes,” said Dr. Gregory Poland of the Mayo Clinic. “You’re looking at a 90% decreased risk of hospitalization and death in a high-risk group — that’s stunning.”
The Food and Drug Administration authorized Pfizer's drug for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalization. That includes older people and those with conditions like obesity and heart disease. Children eligible for the drug must weigh at least 88 pounds (40 kilograms).
The pills from both Pfizer and Merck are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.
Pfizer currently has 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. Federal health officials are expected to ration early shipments to the hardest hit parts of the country. Pfizer said the small supply is due to the manufacturing time — currently about nine months. The company says it can halve production time next year.
The U.S. government has agreed to purchase enough Paxlovid to treat 10 million people. Pfizer says it's on track to produce 80 million courses globally next year, under contracts with the U.K., Australia and other nations.
Health experts agree that vaccination remains the best way to protect against COVID-19. But with roughly 40 million American adults still unvaccinated, effective drugs will be critical to blunting the current and future waves of infection.
The U.S. is now reporting more than 140,000 new infections daily and federal officials warn that the omicron variant could send case counts soaring. Omicron has already whipped across the country to become the dominant strain, federal officials confirmed earlier this week.
Against that backdrop, experts warn that Paxlovid's initial impact could be limited.
For more than a year, biotech-engineered antibody drugs have been the go-to treatments for COVID-19. But they are expensive, hard to produce and require an injection or infusion, typically given at a hospital or clinic. Also, laboratory testing suggests the two leading antibody drugs used in the U.S. aren't effective against omicron.
Pfizer’s pill comes with its own challenges.
Patients will need a positive COVID-19 test to get a prescription. And Paxlovid has only proven effective if given within five days of symptoms appearing. With testing supplies stretched, experts worry it may be unrealistic for patients to self-diagnose, get tested, see a physician and pick up a prescription within that narrow window.
“If you go outside that window of time I fully expect the effectiveness of this drug is going to fall,” said Andrew Pekosz, a Johns Hopkins University virologist.
The FDA based its decision on company results from a 2,250-patient trial that showed the pill cut hospitalizations and deaths by 89% when given to people with mild-to-moderate COVID-19 within three days of symptoms. Less than 1% of patients taking the drug were hospitalized and none died at the end of the 30-day study period, compared with 6.5% of patients hospitalized in the group getting a dummy pill, which included nine deaths.
Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.
The U.S. will pay about $500 for each course of Pfizer's treatment, which consists of three pills taken twice a day for five days. Two of the pills are Paxlovid and the third is a different antiviral that helps boost levels of the main drug in the body.
Fransada 200 bin vaka açıklanmış.
İngiltere 100-150 binlerde dolanıyor.
İspanya ile İtalya 100 bin sınırında.
Omicron'un bulaş etkisi harbiden yüksekmiş
İngiltere 100-150 binlerde dolanıyor.
İspanya ile İtalya 100 bin sınırında.
Omicron'un bulaş etkisi harbiden yüksekmiş
Ağır hastalık yapma oranı daha mı az yoksa aynı mı çok çelişkili ifadeler var, çalışmalar bile çelişebiliyor süre ve örnek sayısı az olduğundan hayırlısıyla bi belli olaydı iyiydi. Yurtdışı kaynaklı yayınlardan bahsediyorum tabi bizde yayın mayın yok.
Son 2 haftada covid olmayani dovuyorlar gibi bir durum soz konusu
☆☆☆☆
☆☆☆☆
Omicron yüzünden karantina zamaninda indirmeyi düsünüyorlarmis bazi ülkeler.